The short answer
DSIP holds no marketing authorisation from the MHRA, EMA or FDA and has not been through regulatory review in any jurisdiction. It carries an International Nonproprietary Name, emideltide, which reflects a WHO naming decision rather than any assessment of safety or efficacy.
Key facts
- MHRA status
- Not authorised
- EMA status
- Not authorised
- FDA status
- Not approved
- INN
- Emideltide, a naming decision only
- UK supply basis
- Laboratory research only
- Claimed indication
- None may be claimed
What an INN is and is not
An International Nonproprietary Name is assigned by the WHO so a substance has one unambiguous generic name worldwide. Assignment happens on request and reflects a need to identify the compound consistently. It says nothing whatsoever about safety, efficacy or approval, and a compound can hold an INN indefinitely without ever being authorised anywhere. DSIP's INN is emideltide.
Why this compound needs the point made clearly
DSIP is unusual among research peptides in carrying a name that asserts a therapeutic effect. A compound called delta sleep-inducing peptide, holding an INN, reads as though it were a medicine at some stage of development. It is not. The name records a 1977 hypothesis, the INN records a naming request, and neither records an assessment by anyone.
Research material referenced
DSIP 5mg, third-party HPLC tested
The claim we do not make
We do not say DSIP induces sleep, improves sleep, or affects sleep in any person. The published basis for such a claim is an EEG observation in rabbits from 1977, with no receptor, no gene and no confirmed mechanism behind it. Making the claim would be inaccurate on the science before it was a problem under the UK framework, where a therapeutic claim about material supplied for research converts it into an unlicensed medicine.
The enforcement context
The MHRA opened investigations into UK retailers making therapeutic claims about unregulated peptide products in April 2026. Sleep claims about a compound literally named for sleep are close to the top of the list of things that framework is concerned with, which is why this category is written the way it is.
What would change the position
A marketing authorisation following an application and assessment. For DSIP specifically that would first require the mechanistic groundwork the field never completed: a receptor, a mechanism, and controlled trials in humans. None of that exists.
Frequently asked questions
Is DSIP legal in the UK?
It is supplied as a material for laboratory research. It is not a licensed medicine and cannot be prescribed or dispensed.
Does having an INN mean DSIP is a drug?
No. An INN is a naming decision by the WHO. It carries no assessment of safety or efficacy and no approval.
Why will you not describe DSIP's effects on sleep?
Because the evidence is a 1977 rabbit EEG observation with no established mechanism, and because a therapeutic claim about research material is what MHRA enforcement targets.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- RefMHRA: Medicines and Healthcare products Regulatory Agencygov.uk
- EMAEuropean Medicines Agencyema.europa.eu
- FDAFDA Drug Approval Searchaccessdata.fda.gov
- PubMedKovalzon VM, DSIP: a still unresolved riddle. J Neurochem 2006 (PMID 16539679)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More DSIP (Delta Sleep-Inducing Peptide) articles
- An Antibody Reports What It Binds, Not What Is ThereRIA generated most of the DSIP distribution literature. It measures immunoreactivity - which is a statement about an antibody, not about a molecule.
- What the Antibody Found in Peripheral TissueGraf and Kastin measured DSIP-like material across 12 rat tissues - highest in stomach - then showed chromatography put most of it at a larger size.
- What Adrenalectomy ChangedBjartell 1991 measured immunoreactive DSIP in rat hypothalamus, pituitary and adrenal gland, and examined what removing the adrenals did to it.
- A Question Mark in the Title Is Doing Real WorkGimble 2009 proposed links between DSIP, glucocorticoid-induced leucine zipper, circadian mechanisms and obesity - and framed it as a question.
- What the Field Said After Its First DecadeGraf published a DSIP update in Peptides in 1986. Reading a review from the middle of a literature shows what was expected but never arrived.